DeutschNewstral
Article
Ppacbiztimes.com on 2023-05-04 18:59
Biosimilar market continues cutting into Amgen’s top line
Related news
- PBiosimilar competition hurts Amgen’s top linepacbiztimes.com
EC Approves Amgen’s Biosimilar Adalimumabjdsupra.com- PFDA approves biosimilar of Amgen’s Neulastapacbiztimes.com
- PFDA approves biosimilar competitor to Amgen’s Enbrelpacbiztimes.com
FDA Approves Novartis’s Biosimilar to Amgen’s Enbrelwsj.com- PFDA approves biosimilar of Amgen’s Enbrelpacbiztimes.com
- PAmgen’s Humira biosimilar delayed, Enbrel approvedpacbiztimes.com
- FDA Approves Amgen’s Biosimilar of Avastin®jdsupra.com
- FDA Approves Amgen’s Biosimilar Version of Humirawsj.com
- PFDA declines to approve Novartis biosimilar for Amgen’s Neulastapacbiztimes.com
- Strike Two – FDA Rejects Amgen’s Certification Petition for Biosimilar Applicantsjdsupra.com
- PStudy shows Amgen’s new biosimilar cancer drug safe, effectivepacbiztimes.com
- New Developments in AbbVie’s BPCIA Suit Targeting Amgen’s Humira® Biosimilarjdsupra.com
Novartis wins US OK for biosimilar version of Amgen’s EnbrelDenver Post- PEuropeans recommend approval of Amgen’s biosimilar of AbbVie’s Humirapacbiztimes.com
- EMA Adopts Positive Opinion for Amgen’s Eculizumab Biosimilar Candidate BEKEMV®jdsupra.com
- FDA: Amgen’s Biosimilar “Highly Similar” to Abbvie’s Humirajdsupra.com
- BREAKING NEWS: FDA Expected to Approve Amgen’s Humira Biosimilar Todayjdsupra.com
- PNovartis biosimilar works as well as Amgen’s Neulastapacbiztimes.com
- Litigation Update: Genentech’s Motion to Dismiss Amgen’s Counterclaims Denied in Avastin Biosimilar Litigationjdsupra.com